- 現金殖利率: 6.56%、總殖利率: 6.56%、5年平均現金配發率: 75.62%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 10.62 | -69.74 | 10.00 | -49.95 | 0.00 | 0 | 94.16 | 65.42 | 0.00 | 0 | 94.16 | 65.42 |
| 2022 (9) | 35.10 | 70.31 | 19.98 | 33.73 | 0.00 | 0 | 56.92 | -21.47 | 0.00 | 0 | 56.92 | -21.47 |
| 2021 (8) | 20.61 | 25.98 | 14.94 | 30.82 | 0.00 | 0 | 72.49 | 3.85 | 0.00 | 0 | 72.49 | 3.85 |
| 2020 (7) | 16.36 | 115.55 | 11.42 | 77.6 | 0.00 | 0 | 69.80 | -17.6 | 0.00 | 0 | 69.80 | -17.6 |
| 2019 (6) | 7.59 | -27.85 | 6.43 | -19.52 | 0.00 | 0 | 84.72 | 11.54 | 0.00 | 0 | 84.72 | 11.54 |
| 2018 (5) | 10.52 | 105.07 | 7.99 | 63.06 | 0.00 | 0 | 75.95 | -20.48 | 0.00 | 0 | 75.95 | -20.48 |
| 2017 (4) | 5.13 | -20.83 | 4.90 | -2.0 | 0.00 | 0 | 95.52 | 23.79 | 0.00 | 0 | 95.52 | 12.54 |
| 2016 (3) | 6.48 | 8.0 | 5.00 | 0.0 | 0.50 | 0.0 | 77.16 | -7.41 | 7.72 | -7.41 | 84.88 | -7.41 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 23Q4 (20) | 1.24 | -63.95 | -70.55 | 1.69 | 10.46 | -59.08 | 10.67 | 13.15 | -70.39 |
| 23Q3 (19) | 3.44 | 89.01 | -59.62 | 1.53 | 350.0 | -79.82 | 9.43 | 57.17 | -70.49 |
| 23Q2 (18) | 1.82 | -56.35 | -89.13 | 0.34 | -89.94 | -97.88 | 6.00 | 43.88 | -74.41 |
| 23Q1 (17) | 4.17 | -0.95 | -37.67 | 3.38 | -18.16 | -37.75 | 4.17 | -88.43 | -37.67 |
| 22Q4 (16) | 4.21 | -50.59 | 37.58 | 4.13 | -45.51 | 119.68 | 36.03 | 12.77 | 68.76 |
| 22Q3 (15) | 8.52 | -49.13 | 34.81 | 7.58 | -52.83 | 15.55 | 31.95 | 36.25 | 74.49 |
| 22Q2 (14) | 16.75 | 150.37 | 147.78 | 16.07 | 195.95 | 215.72 | 23.45 | 250.52 | 95.58 |
| 22Q1 (13) | 6.69 | 118.63 | 27.67 | 5.43 | 188.83 | 89.86 | 6.69 | -68.67 | 27.67 |
| 21Q4 (12) | 3.06 | -51.58 | -3.47 | 1.88 | -71.34 | -37.95 | 21.35 | 16.6 | 25.0 |
| 21Q3 (11) | 6.32 | -6.51 | 61.22 | 6.56 | 28.88 | 70.39 | 18.31 | 52.71 | 30.14 |
| 21Q2 (10) | 6.76 | 29.01 | 12.67 | 5.09 | 77.97 | -11.01 | 11.99 | 128.82 | 17.55 |
| 21Q1 (9) | 5.24 | 65.3 | 26.27 | 2.86 | -5.61 | -15.63 | 5.24 | -69.32 | 26.27 |
| 20Q4 (8) | 3.17 | -19.13 | 5.32 | 3.03 | -21.3 | 20.72 | 17.08 | 21.39 | 112.7 |
| 20Q3 (7) | 3.92 | -34.67 | 115.38 | 3.85 | -32.69 | 109.24 | 14.07 | 37.94 | 178.06 |
| 20Q2 (6) | 6.00 | 44.58 | 275.0 | 5.72 | 68.73 | 429.63 | 10.20 | 145.78 | 215.79 |
| 20Q1 (5) | 4.15 | 37.87 | 153.05 | 3.39 | 35.06 | 177.87 | 4.15 | -48.32 | 153.05 |
| 19Q4 (4) | 3.01 | 65.38 | 0.0 | 2.51 | 36.41 | 0.0 | 8.03 | 58.7 | 0.0 |
| 19Q3 (3) | 1.82 | 13.75 | 0.0 | 1.84 | 70.37 | 0.0 | 5.06 | 56.66 | 0.0 |
| 19Q2 (2) | 1.60 | -2.44 | 0.0 | 1.08 | -11.48 | 0.0 | 3.23 | 96.95 | 0.0 |
| 19Q1 (1) | 1.64 | 0.0 | 0.0 | 1.22 | 0.0 | 0.0 | 1.64 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/3 | 3.72 | 30.13 | -9.7 | 10.78 | -29.78 | 10.78 | N/A | - | ||
| 2024/2 | 2.86 | -31.92 | -34.99 | 7.06 | -37.15 | 10.41 | N/A | - | ||
| 2024/1 | 4.2 | 25.29 | -38.54 | 4.2 | -38.54 | 11.11 | N/A | - | ||
| 2023/12 | 3.35 | -5.6 | -30.61 | 48.07 | -50.06 | 10.78 | 1.12 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/11 | 3.55 | -8.45 | -14.07 | 44.72 | -51.09 | 11.09 | 1.09 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/10 | 3.88 | 6.17 | -57.59 | 41.16 | -52.84 | 10.52 | 1.15 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/9 | 3.65 | 22.38 | -42.53 | 37.28 | -52.29 | 10.01 | 1.3 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/8 | 2.99 | -11.28 | -45.91 | 33.63 | -53.15 | 10.27 | 1.26 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/7 | 3.37 | -14.21 | -72.1 | 30.64 | -53.75 | 11.95 | 1.09 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/6 | 3.92 | -15.79 | -66.77 | 27.28 | -49.67 | 11.92 | 1.06 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/5 | 4.66 | 39.59 | -61.39 | 23.36 | -44.91 | 12.12 | 1.04 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/4 | 3.34 | -19.02 | -73.08 | 18.7 | -38.35 | 11.86 | 1.07 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2023/3 | 4.12 | -6.31 | -27.24 | 15.36 | -14.33 | 15.36 | 0.96 | - | ||
| 2023/2 | 4.4 | -35.64 | -8.69 | 11.24 | -8.37 | 16.07 | 0.91 | - | ||
| 2023/1 | 6.84 | 41.47 | -8.16 | 6.84 | -8.16 | 15.8 | 0.93 | - | ||
| 2022/12 | 4.83 | 16.89 | 8.63 | 96.27 | 48.25 | 18.12 | 0.9 | - | ||
| 2022/11 | 4.13 | -54.82 | -20.82 | 91.44 | 51.17 | 19.64 | 0.83 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/10 | 9.15 | 43.9 | 127.2 | 87.3 | 57.97 | 21.03 | 0.77 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/9 | 6.36 | 15.18 | -4.76 | 78.15 | 52.53 | 23.95 | 0.73 | 本年係因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/8 | 5.52 | -54.24 | -24.57 | 71.79 | 61.11 | 29.39 | 0.59 | 因新冠肺炎抗原快篩檢驗試劑銷售減少 | ||
| 2022/7 | 12.07 | 2.19 | 72.45 | 66.27 | 77.96 | 35.94 | 0.49 | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/6 | 11.81 | -2.16 | 30.83 | 54.21 | 79.23 | 36.28 | 0.57 | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/5 | 12.07 | -2.68 | 171.06 | 42.4 | 99.81 | 30.14 | 0.69 | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/4 | 12.4 | 118.89 | 275.69 | 30.33 | 80.89 | 22.89 | 0.91 | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2022/3 | 5.67 | 17.57 | 31.04 | 17.93 | 33.14 | 17.93 | 0.86 | - | ||
| 2022/2 | 4.82 | -35.27 | 25.38 | 12.26 | 34.13 | 16.71 | 0.92 | - | ||
| 2022/1 | 7.44 | 67.35 | 40.48 | 7.44 | 40.48 | 17.11 | 0.9 | - | ||
| 2021/12 | 4.45 | -14.79 | -21.26 | 64.93 | 10.15 | 13.7 | 1.05 | - | ||
| 2021/11 | 5.22 | 29.62 | 35.73 | 60.48 | 13.48 | 15.93 | 0.91 | - | ||
| 2021/10 | 4.03 | -39.68 | -9.57 | 55.26 | 11.75 | 18.02 | 0.8 | - | ||
| 2021/9 | 6.68 | -8.76 | 22.75 | 51.24 | 13.86 | 20.99 | 0.7 | - | ||
| 2021/8 | 7.32 | 4.61 | 69.1 | 44.56 | 12.64 | 23.34 | 0.63 | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2021/7 | 7.0 | -22.47 | 34.32 | 37.24 | 5.7 | 20.47 | 0.72 | - | ||
| 2021/6 | 9.02 | 102.68 | 93.22 | 30.24 | 0.74 | 16.78 | 0.88 | 因新冠肺炎抗原快篩檢驗試劑銷售增加 | ||
| 2021/5 | 4.45 | 34.88 | -30.03 | 21.22 | -16.29 | 12.08 | 1.22 | - | ||
| 2021/4 | 3.3 | -23.65 | -48.0 | 16.77 | -11.69 | 11.47 | 1.29 | - | ||
| 2021/3 | 4.32 | 12.5 | -17.19 | 13.47 | 6.54 | 13.47 | 1.11 | - | ||
| 2021/2 | 3.84 | -27.47 | -6.82 | 9.14 | 23.24 | 14.79 | 1.01 | - | ||
| 2021/1 | 5.3 | -6.2 | 60.91 | 5.3 | 60.91 | 14.79 | 1.01 | 因新冠肺炎額溫槍銷售增加 | ||
| 2020/12 | 5.65 | 46.88 | 23.88 | 58.95 | 42.29 | 13.95 | 1.09 | - | ||
| 2020/11 | 3.85 | -13.64 | 3.83 | 53.3 | 44.57 | 13.74 | 1.11 | - | ||
| 2020/10 | 4.45 | -18.11 | 35.55 | 49.45 | 49.12 | 14.22 | 1.07 | - | ||
| 2020/9 | 5.44 | 25.67 | 102.97 | 45.0 | 50.61 | 14.98 | 1.01 | 因武漢肺炎額溫銷售增加 | ||
| 2020/8 | 4.33 | -16.89 | 21.03 | 39.56 | 45.45 | 14.21 | 1.07 | - | ||
| 2020/7 | 5.21 | 11.52 | 38.66 | 35.23 | 49.15 | 16.24 | 0.93 | - | ||
| 2020/6 | 4.67 | -26.6 | 40.04 | 30.02 | 51.14 | 17.38 | 0.84 | 因武漢肺炎額溫槍銷售增加 | ||
| 2020/5 | 6.36 | 0.23 | 83.83 | 25.35 | 53.38 | 17.93 | 0.81 | 因武漢肺炎額溫槍銷售增加 | ||
| 2020/4 | 6.35 | 21.59 | 105.13 | 18.99 | 45.31 | 15.69 | 0.93 | 因武漢肺炎額溫槍銷售増加 | ||
| 2020/3 | 5.22 | 26.58 | 47.64 | 12.64 | 26.74 | 12.64 | 0.86 | - | ||
| 2020/2 | 4.12 | 25.24 | 55.68 | 7.42 | 15.26 | 11.98 | 0.91 | 因武漢肺炎額溫槍銷售增加 | ||
| 2020/1 | 3.29 | -27.78 | -13.02 | 3.29 | -13.02 | 11.56 | 0.94 | - | ||
| 2019/12 | 4.56 | 23.1 | 11.61 | 41.42 | -4.69 | 11.55 | 0.82 | - | ||
| 2019/11 | 3.7 | 12.73 | -10.51 | 36.86 | -6.39 | 9.67 | 0.98 | - | ||
| 2019/10 | 3.29 | 22.6 | -16.82 | 33.16 | -5.9 | 9.54 | 0.99 | - | ||
| 2019/9 | 2.68 | -25.05 | -37.74 | 29.87 | -4.52 | 10.01 | 1.03 | - | ||
| 2019/8 | 3.58 | -4.79 | -1.84 | 27.19 | 0.76 | 10.67 | 0.96 | - | ||
| 2019/7 | 3.76 | 12.63 | -14.41 | 23.62 | 1.17 | 10.55 | 0.97 | - | ||
| 2019/6 | 3.33 | -3.65 | -3.52 | 19.86 | 4.78 | 9.89 | 1.13 | - | ||
| 2019/5 | 3.46 | 11.85 | -7.04 | 16.53 | 6.63 | 0.0 | N/A | - | ||
| 2019/4 | 3.09 | -12.48 | 1.13 | 13.07 | 10.96 | 0.0 | N/A | - |
